AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard & Poor's, priced a successful debut eurobond transaction (the "Bonds") issuing a total of EUR750 million. The proceeds of the issue will be used for general corporate purposes and to repay a portion of the outstanding US commercial paper taken on in connection with the acquisition of MedImmune.

The transaction is issued off a new Euro Medium Term Note (EMTN) programme, dated September 10th 2007, and is a EUR750 million, fixed rate issue with a coupon of 5.125% maturing in January 2015.

"This transaction represents a further part of our refinancing of the acquisition of MedImmune Inc, following our successful $6.9bn, 4-tranche SEC Global issue last week. As with last week's issue, this transaction represents an enhancement of our financial flexibility by diversifying further our sources of funding. We undertook an extensive roadshow of investor meetings in London, Paris and Frankfurt and are very pleased with the feedback on the AstraZeneca credit, and the reception for us in the bond markets", said David Brennan, Chief Executive Officer of AstraZeneca.

The Bonds will be issued to institutional investors outside the US in accordance with Regulation S of the U.S. Securities Act 1933. The Bonds will be admitted to listing on the UKLA's Official List and to trading on the London Stock Exchange's Fixed Income and Gilt Edged Market.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading bio-pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information, visit www.astrazeneca.com.